Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

Inclusion Criteria

• •Mantle cell lymphoma (MCL) confirmed with histology, immunophenotype, and cyclin D1 analysis
• •Received 2 to 7 prior therapies which may include hematopoietic stem cell transplant (i.e. induction + consolidation + maintenance)
• •Prior treatment with an alkylating agent and an anthracycline, rituximab, individually or in combination, and status that is at least one of the following:
• •Primary disease refractory to at least 2 regimens;
• •Refractory to at least 1 regimen after first relapse;
• •Refractory or untreated after second or greater relapse;
• •Refractory to first line and relapsed after second line. Chemotherapy combinations may include, but are not limited to: CHOP (Cyclophosphamide, doxorubicin, vincristine, prednisone), R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone), FCM (Fludarabine, cyclophosphamide, mitoxantrone), R-FCM (Rituximab,Fludarabine, cyclophosphamide, mitoxantrone), ICE(Ifosfamide, carboplatin, etoposide), DHAP (Dexamethasone, cisplatin, cytarabine) and hyper-CVAD (Cyclophosphamide, doxorubicin, vincristine, dexamethasone).